BANK VONTOBEL/CALL/BIONTECH ADR/100/0.01/20.06.25 Share Price

Warrant

DE000VM75G45

Real-time Boerse Frankfurt Warrants 18:41:52 28/06/2024 BST
0.072 EUR -5.26% Intraday chart for BANK VONTOBEL/CALL/BIONTECH ADR/100/0.01/20.06.25
1 month-48.57%
3 months-53.85%
Date Price Change
28/06/24 0.072 -5.26%
27/06/24 0.076 -7.32%
26/06/24 0.082 -11.83%
25/06/24 0.093 -7.92%
24/06/24 0.101 +10.99%

Real-time Boerse Frankfurt Warrants

Last update June 28, 2024 at 06:41 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer Vontobel Vontobel
WKN VM75G4
ISINDE000VM75G45
Date issued 08/01/2024
Strike 100 $
Maturity 20/06/2025 (355 Days)
Parity 100 : 1
Emission price 0.3
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.33
Lowest since issue 0.072
Delta0.43x
Omega 3.952
Premium35.43x
Gearing9.1x
Moneyness 0.8036
Difference Strike 19.64 $
Difference Strike %+19.64%
Spread 0.01
Spread %11.49%
Theoretical value 0.0820
Implied Volatility 43.88 %
Total Loss Probability 72.51 %
Intrinsic value 0.000000
Present value 0.0820
Break even 108.83 €
Theta-0x
Vega0x
Rho0x

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
75 EUR
Average target price
103.5 EUR
Spread / Average Target
+38.03%
Consensus